In summary, these findings suggest that CXCL17 contributes to OSCC progression and poor prognosis by modulating systemic immune responses and reshaping the tumor immune microenvironment, highlighting its potential as both a prognostic biomarker and a therapeutic target. This evidence concerns the gene CXCL17 and neoplasm.